| Renal Cell Carcinoma
Inlyta vs Torisel
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Inlyta vs Torisel with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTorisel has a higher rate of injection site reactions vs Inlyta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Torisel but not Inlyta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Inlyta
Torisel
At A Glance
Oral
Twice daily
VEGFR tyrosine kinase inhibitor
IV infusion
Once weekly
mTOR inhibitor
Indications
- Renal Cell Carcinoma
- Renal Cell Carcinoma
Dosing
Renal Cell Carcinoma (first-line, with avelumab) 5 mg orally twice daily combined with avelumab 800 mg IV every 2 weeks; dose escalation may be considered at intervals of 2 weeks or longer.
Renal Cell Carcinoma (first-line, with pembrolizumab) 5 mg orally twice daily combined with pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks IV; dose escalation may be considered at intervals of 6 weeks or longer.
Renal Cell Carcinoma (second-line, single agent) Starting dose 5 mg orally twice daily approximately 12 hours apart, with or without food; doses may be increased to 7 mg or 10 mg twice daily based on tolerability, or reduced to 3 mg or 2 mg twice daily for adverse reactions.
Renal Cell Carcinoma 25 mg administered as an IV infusion over 30-60 minutes once weekly; continue until disease progression or unacceptable toxicity.
Contraindications
—
- Bilirubin >1.5x ULN
Adverse Reactions
Most common (>=20%) Diarrhea, fatigue, hypertension, hepatotoxicity, hypothyroidism, decreased appetite, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, musculoskeletal pain, constipation
Serious Hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, hepatotoxicity
Postmarketing Arterial aneurysms, dissections, and rupture (including aortic)
Most common (>=30%) Rash, asthenia, mucositis, nausea, edema, anorexia
Serious Hypersensitivity/infusion reactions, hepatic impairment, hyperglycemia/glucose intolerance, infections, interstitial lung disease, hyperlipidemia, bowel perforation, renal failure, wound healing complications, intracerebral hemorrhage
Postmarketing Angioedema, rhabdomyolysis, Stevens-Johnson Syndrome, complex regional pain syndrome, pancreatitis, cholecystitis, cholelithiasis
Pharmacology
Axitinib is a selective inhibitor of receptor tyrosine kinases including VEGFR-1, VEGFR-2, and VEGFR-3, which are implicated in pathologic angiogenesis, tumor growth, and cancer progression; VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse models.
Temsirolimus is an mTOR inhibitor that binds to FKBP-12; the protein-drug complex inhibits mTOR activity, blocking phosphorylation of p70S6k and S6 ribosomal protein downstream in the PI3 kinase/AKT pathway, resulting in G1 growth arrest in tumor cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inlyta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
Torisel
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Inlyta
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (3/8)
Torisel
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Inlyta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (2/3)
Torisel
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Renal Cell Carcinoma (RCC): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Renal Cell Carcinoma (RCC): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InlytaView full Inlyta profile
ToriselView full Torisel profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.